Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS
September 19th 2023Uwe Platzbecker, MD, discusses how the FDA approval of luspatercept for the treatment of anemia in patients who have not had prior treatment with erythropoiesis-stimulating agent and may require regular red blood cell transfusions could change the sequencing of agents for this patient population.
Patient preferences should be considered when selecting the optimal treatment regimen for patients with relapsed/refractory follicular lymphoma, as both CD19-directed CAR T-cell therapies and CD20-targeted bispecific antibodies can be efficacious in this population, according to a presentation by Caron A. Jacobson, MD, MMSc, at the 2023 SOHO Annual Meeting.
JAK Inhibitors Continue to Shape the Treatment Landscape of Myelofibrosis
September 12th 2023Following the FDA approvals of the JAK inhibitors ruxolitinib, fedratinib, and pacritinib, the treatment landscape of myelofibrosis continues to grow with the use of these agents with an additional FDA review planned for momelotinib in September 2023.
Dr Garcia-Manero on the Efficacy of Luspatercept in Transfusion-Dependent MDS
September 9th 2023Guillermo Garcia-Manero, MD, discusses the key efficacy findings from the phase 3 COMMANDS trial evaluating luspatercept-aamt in patients with myelodysplastic syndrome who were erythropoiesis-stimulating agent naïve and red blood cell transfusion dependent.
Quizartinib Improves OS Irrespective of Allo-HCT in CR1 and Pre-Allo MRD Status in FLT3-ITD+ AML
Quizartinib plus standard intensive induction and consolidation therapy resulted in improved overall survival compared with placebo in patients with newly diagnosed, FLT3-ITD–positive AML irrespective of allogeneic hematopoietic cell transplantation in first complete remission and pre-allo minimal residual disease status.
Subcutaneous Epcoritamab Elicits Durable Responses in Relapsed/Refractory LBCL
Subcutaneous epcoritamab produced deep and durable complete remissions in patients with relapsed or refractory large B-cell lymphoma, with complete responders having favorable long-term outcomes, according to updated data from the phase 1/2 EPCORE NHL-1 trial.
Dr Nastoupil on the Investigation of Liso-Cel in Relapsed/Refractory Follicular Lymphoma
September 8th 2023Loretta J. Nastoupil, MD, discusses the safety and efficacy data from the phase 2 TRANSCEND FL trial evaluating lisocabtagene maraleucel in patients with relapsed/refractory follicular lymphoma.
Quizartinib Plus Induction Chemotherapy Provides Survival Benefit in FLT3 ITD–Mutated AML
September 8th 2023The addition of quizartinib to induction and consolidation chemotherapy, followed by single-agent quizartinib for up to 36 cycles, improved survival outcomes vs placebo in patients with FLT3 ITD–mutated, newly diagnosed acute myeloid leukemia.
Without a plethora of randomized and historic data to compare treatments, selection and sequencing strategies for patients with relapsed/refractory multiple myeloma must balance a multitude of factors, including adverse effect profiles, disease resistance mechanisms, and more.
Improved Molecular Understanding of AP/BP MPN Better Informs Management Approaches
September 8th 2023Developing an optimal treatment strategy for patients with accelerated- or blast-phase myeloproliferative neoplasms requires consideration of a patient's ability to tolerate intensive induction therapy, their eligibility for allogeneic stem cell transplant.
Minimal residual disease negativity sustained for 6 months or longer with ciltacabtagene autoleucel prolonged duration of response and progression-free survival compared with minimal residual disease negativity sustained for less than 6 months in patients with heavily pretreated relapsed/refractory multiple myeloma.
Ongoing Investigations of Nelabarine and Daratumumab May Improve Outcomes in T-ALL
September 8th 2023Investigating the addition of novel agents to cytotoxic chemotherapy may help prevent relapse in patients with T-cell acute lymphoblastic leukemia by bolstering the efficacy of these standard frontline therapies.
Survival Outcomes May Be Impacted By Socio-Racial Factors in Primary Myelofibrosis
A retrospective analysis of the Surveillance, Epidemiology, and End Results database emphasized the potential impact of specific socio-racial factors, such as race, sex, and age, on survival outcomes in patients with primary myelofibrosis.
Dr Lin on the Outcomes of MRD-Negative Patients With R/R Myeloma After Cilta-Cel
September 7th 2023Yi Lin, MD, PhD, discusses the patient characteristic for those with relapsed/refractory multiple myeloma who experienced sustained minimal residual disease negativity following treatment with ciltacabtagene autoleucel during the phase 1/2 CARTITUDE-1 trial.
Intensity of Consolidation Pre-Transplant Shows No Difference in Outcomes in Older AML
September 7th 2023No difference in relapse-free survival or non–relapse mortality was seen with intensive vs non-intensive consolidation chemotherapy regimens prior to allogeneic hematopoietic stem cell transplantation in elderly patients over the age of 60 with acute myeloid leukemia in first complete remission.
Understanding How to Best Measure MRD Negativity in Ph+ ALL
September 7th 2023The implementation of treatment with later-generation BCR-ABL1 TKIs like ponatinib and chemotherapy-free combination regimens with blinatumomab plus a TKI have greatly pushed the treatment armamentarium of Philadelphia chromosome–positive acute lymphoblastic leukemia forward.
PhaseEd-Seq MRD Detection May Provide Effective Alternative to Standard Imaging in LBCL
Current research suggests that circulating tumor DNA may have prognostic value when conducted at the conclusion of treatment in large B-cell lymphoma, indicating that minimal residual disease detection using ctDNA assessments such as PhaseEd-Seq could address imitations associated with the use of computed tomography or positron emission tomography/CT scans at this stage.
Early Cytogenetic or Molecular Landmark Response to Ponatinib Predicts Outcomes in CP-CML
Early cytogenetic and molecular responses achieved with ponatinib was significantly linked with better long-term progression-free survival and overall survival in patients with highly resistant, pretreated chronic-phase chronic myeloid leukemia.
Health Outcomes in Hematologic Malignancies Impacted By Insurance, Marital, and Economic Status
September 7th 2023Findings from a systematic review of several observational studies reveal that increasing disparities in survival outcomes within hematologic malignancies can be primarily attributed to 5 social determinants of health: lack of access to health insurance, treatment at a non-academic facility, low income or education level, and unmarried status.
Luspatercept Displays Superiority Over ESA in RBC Transfusion-Dependent MDS
The phase 3 COMMANDS trial investigating the use of luspatercept in patients with myelodysplastic syndrome who had not received an erythropoiesis-stimulating agent and were red blood cell transfusion dependent achieved its primary end point of superiority over treatment with an erythropoiesis-stimulating agent.
Ongoing Research on MRD Detection May Shift Outcomes for Posttransplant AML
September 7th 2023The prediction of relapse following treatment with allogeneic stem cell transplant in patients with acute myeloid leukemia in first complete remission remains an unmet need due to limitations attributed to measurable residual disease detection methods.
Ponatinib Increases MRD-Negative CR Rate in Ph+ ALL
The addition of the TKI ponatinib to reduced-intensity chemotherapy led to an increase in minimal residual disease-negative complete remission rate at the end of induction compared with imatinib among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Outcomes With Pediatric-Inspired Regimens Warrant Further Exploration in AYA PH- ALL
September 6th 2023Varying outcomes were observed among adolescent and young adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia who were treated with pediatric-inspired protocols vs adult chemotherapy regimens.
Bispecific Antibodies May Revolutionize the Management of B-Cell Lymphoma
September 6th 2023The safety profiles and the high response rates observed with bispecific antibodies in patients with B-cell lymphoma suggest that these agents possess the potential to revolutionize the management of these diseases, particularly follicular lymphoma.